Selection of the proper target is crucial for clinically relevant monitoring of minimal residual disease (MRD) in patients with acute lymphoblastic leukemia using the quantitation of clonal-specific immunoreceptor (immunoglobulin/T cell receptor) gene rearrangements. Consequently, correct interpretation of the results of the entire analysis is of utmost importance. Here we present an overview of the quality control measures that need to be implemented into the process of marker identification, selection, and subsequent quantitation of the MRD level.

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Pongers-Willemse M, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P et al (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13:110–118. https://doi.org/10.1038/sj.leu.2401245 doi: 10.1038/sj.leu.2401245. PubMed DOI

Szczepański T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER et al (1999) Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 93:4079–4085 PubMed

Van Dongen JJM, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317. https://doi.org/10.1038/sj.leu.2403202 doi: 10.1038/sj.leu.2403202. PubMed DOI

Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241–2253. https://doi.org/10.1038/s41375-019-0496-7 doi: 10.1038/s41375-019-0496-7. PubMed DOI PMC

Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V et al (2019) Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33:2254–2265. https://doi.org/10.1038/s41375-019-0499-4 doi: 10.1038/s41375-019-0499-4. PubMed DOI PMC

Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A et al (2017) ARResT/interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics 33:435–437. https://doi.org/10.1093/bioinformatics/btw634 doi: 10.1093/bioinformatics/btw634. PubMed DOI

Giraud M, Salson M, Duez M, Villenet C, Quief S, Caillault A et al (2014) Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics 15:409. https://doi.org/10.1186/1471-2164-15-409 doi: 10.1186/1471-2164-15-409. PubMed DOI PMC

Van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611. https://doi.org/10.1038/sj.leu.2404586 doi: 10.1038/sj.leu.2404586. PubMed DOI

Van der Velden VHJ, Hochhaus A, Cazzaniga G, Zczepanski T, Gabert J, van Dongen JJ (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17:1013–1034. https://doi.org/10.1038/sj.leu.2402922 doi: 10.1038/sj.leu.2402922. PubMed DOI

Van der Velden VHJ, Wijkhuijs JM, van Dongen JJM (2008) Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia 22:641–644. https://doi.org/10.1038/sj.leu.2404925 doi: 10.1038/sj.leu.2404925. PubMed DOI

Fronkova E, Muzikova K, Mejstrikova E, Kovac M, Formankova R, Sedlacek P et al (2008) B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant 42:187–196. https://doi.org/10.1038/bmt.2008.122 doi: 10.1038/bmt.2008.122. PubMed DOI

Kotrova M, Van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Brüggemann M et al (2017) Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant 52(7):962–968. https://doi.org/10.1038/bmt.2017.16 doi: 10.1038/bmt.2017.16. PubMed DOI

Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines